Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Phase 2

Not yet recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC V8
Metastatic Breast Carcinoma
Recurrent Breast Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Radiation: Gallium Ga 68-DOTATATE
Drug: Lutetium Lu 177 Dotatate
Procedure: Positron Emission Tomography

First Posted Date: 2020-08-27

Last Posted Date: 2024-12-20

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 10

Registration Number: NCT04529044

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Not Applicable

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm
Breast Ductal Carcinoma In Situ
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Lynch Syndrome
Hereditary Neoplastic Syndrome
Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Genetic Counseling
Other: Genetic Testing
Other: Survey Administration

First Posted Date: 2020-07-31

Last Posted Date: 2024-10-31

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 27500

Registration Number: NCT04494945

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC V8
Anatomic Stage IA Breast Cancer AJCC V8
Anatomic Stage IB Breast Cancer AJCC V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage IIA Breast Cancer AJCC V8
Anatomic Stage IIB Breast Cancer AJCC V8
Anatomic Stage IIIA Breast Cancer AJCC V8
HER2 Negative Breast Adenocarcinoma
Hormone Receptor Positive Breast Adenocarcinoma
Invasive Breast Carcinoma

Interventions: Drug: Abemaciclib
Drug: Niraparib Tosylate Monohydrate

First Posted Date: 2020-07-22

Last Posted Date: 2024-10-17

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 8

Registration Number: NCT04481113

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Phase 2

Terminated

Conditions: Lymphoma
Malignant Solid Neoplasm
Plasma Cell Myeloma

Interventions: Drug: Xisomab 3G3

First Posted Date: 2020-07-10

Last Posted Date: 2024-01-24

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 9

Registration Number: NCT04465760

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

Phase 2

Withdrawn

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions: Drug: Lopinavir/Ritonavir
Drug: Placebo Administration
Other: Questionnaire Administration

First Posted Date: 2020-07-02

Last Posted Date: 2021-04-26

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT04455958

Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

Terminated

Conditions: Stage I Pancreatic Cancer AJCC v8
Pancreatic Ductal Adenocarcinoma
Stage IA Pancreatic Cancer AJCC v8
Stage IB Pancreatic Cancer AJCC v8

Interventions: Device: Activity Monitor
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-05-26

Last Posted Date: 2022-11-22

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 110

Registration Number: NCT04400903

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Virtual Reality for the Education of Cancer Patients Undergoing Radiation Therapy

Not Applicable

Terminated

Conditions: Malignant Neoplasm

Interventions: Other: Educational Intervention
Other: Survey Administration

First Posted Date: 2020-02-20

Last Posted Date: 2023-08-30

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 27

Registration Number: NCT04278534

Locations: 🇺🇸
Compass Oncology Rose Quarter, Portland, Oregon, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-Sensitive Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma

Interventions: Drug: Abiraterone Acetate
Drug: Antiandrogen Therapy
Drug: Apalutamide
Drug: Prednisone
Procedure: Computed Tomography
Procedure: Bone Scan
Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2020-02-13

Last Posted Date: 2024-08-12

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 7

Registration Number: NCT04267887

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Phase 2

Active, not recruiting

Conditions: Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8
Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Liver and Intrahepatic Bile Duct Carcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Unresectable Intrahepatic Cholangiocarcinoma

Interventions: Drug: Dexamethasone
Drug: Floxuridine
Device: Implanted Medical Device
Drug: Irinotecan
Drug: Leucovorin
Drug: Oxaliplatin
Other: Quality-of-Life Assessment

First Posted Date: 2020-02-05

Last Posted Date: 2024-03-08

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 5

Registration Number: NCT04251715

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Progressive Resistance Training for the Improvement of Physical Function

Not Applicable

Completed

Conditions: Sarcoma

Interventions: Other: Exercise Counseling
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Other: Resistance Training

First Posted Date: 2020-01-30

Last Posted Date: 2022-08-08

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 10

Registration Number: NCT04247425

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy